Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Axsome Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Axsome Therapeutics, Inc.

AXSM

Axsome Therapeutics, Inc.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel oral therapies for central nervous system (CNS) disorders. Its portfolio includes FDA-approved products for major depressive disorder, excessive daytime sleepiness, and acute migraine treatment, alongside late-stage candidates for Alzheimer’s agitation, narcolepsy, fibromyalgia, and other CNS conditions. Axsome leverages proprietary formulation technologies and targets underserved CNS markets with high unmet medical needs, primarily serving patients and healthcare providers in the U.S.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Axsome Therapeutics, Inc.

1
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports 57.4% Revenue Growth to $191.2 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports 66% Revenue Growth to $638.5 Million for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports $171M Revenue in Q3 2025, Net Loss Decreases

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports $150M Revenue for Q2 2025, Significant Year-Over-Year Growth

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports $121.5 Million in Revenue, Net Loss Decreases to $59.4 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports $287.2 Million Net Loss and $381.7 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Axsome Therapeutics, Inc. Axsome Therapeutics Reports Significant Revenue Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments